Clinical Trial Detail

NCT ID NCT03329937
Title Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements yes
Sponsors Tesaro, Inc.
Indications

Her2-receptor negative breast cancer

Therapies

Niraparib

Age Groups: adult senior

Additional content available in CKB BOOST